Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Myeloproliferative Disorders 1Hematologic Neoplasms 1

Interventions

ruxolitinib 7givinostat hydrochloride 3givinostat 3anagrelide 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3bomedemstat 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2LY2784544 2spartalizumab 1sonidegib 1sabatolimab 1navitoclax 1lestaurtinib 1imetelstat 1ON 01910 1NIS-793 1N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 1INCB057643 1Fentanyl 1Diagnosis 1Decitabine 1Celecoxib 1CPI-0610 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Thrombocythemia, Essential × LY2784544 × Clear all
NCT01134120 2018-04-17

A Study in Myeloproliferative Disorders

Eli Lilly and Company

Phase 1 Completed
80 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT01520220 2017-04-12

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

Eli Lilly and Company

Phase 1 Completed
100 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡